Allogene Therapeutics is advancing its pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with key results expected by mid-2027. Early clinical data for ALLO-329 in autoimmune diseases highlight a unique CAR-T platform using proprietary technology. The company improved financial discipline by reducing its quarterly net loss to $42.6 million and extended its cash runway into early 2029 after raising $200.4 million in a public offering. Upcoming catalysts include a fourth-quarter 2026 update on ALLO-329 and the mid-2027 ALPHA3 event-free survival readout, which could drive stock revaluation.
Chery Auto officially opened its Rosslyn Plant in South Africa, transforming from an importer to a local manufacturer and retaining all 692 employees. The plant, originally built in 1963, will be upgraded to produce 50,000 vehicles annually by mid-20...
The MARS2 Multimodal Reasoning Competition, sponsored by Tec-Do and MiniMax, has been officially launched to coincide with the ECCV 2026 conference. With a $100,000 prize pool, the competition challenges AI models to perform complex, open-world reaso...
Open USD introduces a new stablecoin model that shares reserve yield with distribution partners instead of the issuer, aiming to realign incentives for wallets, payment processors, and fintechs. This approach could disrupt USDC's long-standing domina...
PEPE memecoin surged 14.06% in 24 hours, driven by increased spot buying and trading volume, signaling renewed market interest. The token's market cap reached $1.16 billion as spot volume grew faster than futures, indicating direct buying rather than...
XRP has surged more than 8% recently, breaking out of a price range and forming a golden cross against Bitcoin on the 2-hour chart, signaling growing bullish momentum. This technical indicator, where the 50-day moving average crosses above the 200-da...
